A Decade-Plus of Ethical Failures at Marseille's IHU: What the Latest Investigation Found
An international team of scientists has identified what they call "substantial" ethical and legal problems across 853 research articles published by the Institut Hospitalo-Universitaire Méditerranée Infection (IHU) in Marseille, France. The findings, published in a peer-reviewed follow-up investigation, cover IHU publications from 1994 to 2024. Didier Raoult, the virologist who led IHU until his retirement, appears as a co-author on 758 of the 853 flagged papers. The investigation, conducted by researcher F. Frank, documented patterns including the repeated reuse of ethics approvals — the official permissions that allow researchers to run studies involving human participants. Reusing those approvals violates both French and European rules governing clinical research The Guardian; Springer.
The findings cap years of escalating scrutiny. In 2022, Aix-Marseille University investigated and found ethical breaches in eight papers, seven co-authored by Raoult. A follow-up investigation into IHU's ethics approvals, published in August 2026, found non-compliance with French and European laws Retraction Watch. Science reported in November 2024 that a previously unearthed university investigation had concluded that studies by Raoult and colleagues violated French and international ethical standards Science. Two journals of a leading microbiology society retracted six Raoult-authored articles in January 2024 following a university investigation. By April 2024, an Elsevier journal had issued over 100 expressions of concern — formal notices alerting readers that published papers may have serious problems — for papers from Raoult's research group Retraction Watch; Retraction Watch. French prosecutors also opened a criminal investigation into IHU after a regulator report alleged forgery and "several serious breaches" of clinical research rules Times Higher Education.
The scale of the Frank investigation — 853 articles across three decades — dwarfs earlier institutional responses. A 2023 paper by Frank had already reviewed ethical statements in IHU publications; the 2026 follow-up expanded that work into the comprehensive tally now reported. Taken together, the sequence of findings, institutional investigations, prosecutorial action, and journal-level retractions and expressions of concern points toward systemic ethical failure rather than isolated lapses.
Raoult's global prominence dates to March 2020, when he and colleagues published research claiming that hydroxychloroquine, particularly combined with azithromycin, was an effective Covid-19 treatment. That paper was later retracted in 2025 for ethical and scientific reasons. At the time, though, the findings were amplified at the highest political levels. Donald Trump called Raoult's hydroxychloroquine research a "gamechanger" during the pandemic. Dr. Mehmet Oz, now head of the US Centers for Medicare and Medicaid Services, echoed that endorsement. French president Emmanuel Macron made a high-profile visit to IHU and met personally with Raoult The Guardian.
The broader context here is what the IHU case reveals about how scientific claims get absorbed by policy during crises. The hydroxychloroquine episode is more than a case study in scientific retractions. It shows how a single researcher with institutional authority and media presence can shape global clinical practice before peer review — the system where other scientists check a study's methods and findings — and regulatory oversight have time to function. The retraction of the hydroxychloroquine paper in 2025, five years after publication, illustrates the lag between the fast spread of early-stage research and the slower machinery of scientific correction.
For institutions and journals, the IHU case raises unresolved questions about whether post-publication oversight can operate at the necessary scale. The Elsevier expressions of concern alone exceed 100 papers. The Frank investigation tallies 853. Retraction processes, while functioning, operate on timelines measured in years — during which cited and clinically deployed findings continue to shape medical practice. The repeated reuse of ethics approvals across IHU publications points to a failure mode that institutional review boards are not currently structured to detect at scale, since they typically review research plans before studies begin rather than auditing compliance across a researcher's full body of work.
The criminal investigation into IHU, opened after a regulator report alleged forgery and serious clinical research breaches, is the most consequential unresolved thread. Prosecutorial involvement moves the matter beyond academic misconduct into potential fraud charges under French law. How French authorities handle the case may set precedent for how systemic research ethics violations are prosecuted when they span decades and hundreds of publications.
